Aciphex  

Rabeprazole
Systematic (IUPAC) name
2-([4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methylsulfinyl)-1H-benzo[d]imidazole
Identifiers
CAS number	117976-89-3
ATC code	A02BC04
PubChem	5029
DrugBank	APRD01212
ChemSpider	4853
Chemical data
Formula	C18H21N3O3S
Mol. mass	359.444 g/mol
SMILES	eMolecules & PubChem
Pharmacokinetic data
Bioavailability	52%
Metabolism	Hepatic
Half life	1 - 1.5 hours
Excretion	Renal
Therapeutic considerations
Licence data	US FDA:link
Pregnancy cat.	B(US)
Legal status	POM(UK) -only(US)
Routes	Oral
Y(what is this?)  (verify)

Rabeprazole is an antiulcer drug in the class of proton pump inhibitors. It was developed by Eisai Co. and is marketed by Janssen-Cilag as rabeprazole sodium under the brand names AcipHex (pronounced "acifex", referring to pH) in the US, Pariet in Japan and Canada, & Rablet in India.

Indications and usage

Short-term treatment in healing and symptomatic relief of duodenal ulcers and erosive or ulcerative gastroesophageal reflux disease (GERD); maintaining healing and reducing relapse rates of heartburn symptoms in patients with GERD; treatment of daytime and nighttime heartburn and other symptoms associated with GERD; long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome and in combination with amoxicillin and clarithromycin to eradicate Helicobacter pylori.

• Gastric ulcer
• Peptic ulcer disease (PUD)
• Maintenance of healing of erosive or ulcerative GERD
• Healing of erosive and ulcerative GERD
• Healing of duodenal ulcers.
• Treatment of symptomatic GERD
• Treatment of pathological hypersecretory conditions (Zollinger-Ellison syndrome)
• Helicobacter pylori eradication to reduce risk of duodenal ulcer recurrence

Contraindications

• hypersensitivity to rabeprazole, substituted benzimidazoles or any of components of its pharmaceutical forms.
• pregnancy: FDA Pregnancy Ratings: B
• lactation: Thomson Lactation Ratings: Infant risk cannot be ruled out.

Restriction of usage

Bottle of rabeprazole 20 mg tablets.

• acute hepatic failure
• pediatric use in patients under 18 years of age (there are insufficient data about safety and efficiency of rabeprazole in this group of patients)

Side effects

Rabeprazole adverse reactions/side effects include^{[citation needed]}:

• In clinical trials the most common side effect assessed as possibly or probably related to AcipHex was headache in 2.4% of patients vs 1.6% taking placebo.
• diarrhea
• vomiting
• nausea
• abdominal pains
• constipation
• meteorism
• dry mouth
• increased or decreased appetite
• asthenia
• headache
• anxiety
• sleeplessness
• vertigo
• thrombocytopenia
• granulocytopenia
• leukocytopenia
• skin eruption
• erythema
• myalgia
• arthralgia
• muscle or bone pain

Drug interactions

Rabeprazole decreases the concentration of ketoconazole in the plasma (in 33%), increases the concentration of digoxin (in 22%), and does not interact with liquid antacids. Rabeprazole is compatible with any medicine metabolized by the CYP450 (theophylline, warfarin, diazepam, phenytoin). can be safe in pregnancy

Overdosage

There is no available data on symptoms of rabeprazole overdose.

How supplied

Rabeprazole as Rablet (Lupin), AcipHex, Rabeloc, Pariet is supplied in:

• Tablet, enteric-coated; 10mg
• Tablet, enteric-coated; 20mg

References

• Morii M, Takata H, Fujisaki H, Takeguchi N., The potency of substituted benzimidazoles such as E3810, omeprazole, Ro 18-5364 to inhibit gastric H+, K(+)-ATPase is correlatedwith the rate of acid-activation of the inhibitor, Biochem. Pharmacol. 1990 Feb 15;39(4):661-7.
• Prakash A, Faulds D., Rabeprazole, Drugs. 1998 Feb;55(2):261-7; discussion 268.

External links

• AcipHex official product site
• AcipHex review

Recent Aciphex Forums  View All  

Aciphex DOES USE OF ACIPHEX CAUSE WEIGHT GAIN? Saturday, 4/22/2006 10:18:17 AM  1 Reply

Physician thanks Wednesday, 9/28/2005 7:27:02 AM  Post a Reply